Evidence map›Paper›PMID 29375020›Full record

ArticleTechnology in cancer research & treatment2018

Novel Cancer Stem Marker and Its Applicability for Grading Primary Human Gliomas.

Evgeniya V Dolgova, Sergey V Mishinov, Anastasiya S Proskurina, Ekaterina A Potter, Yaroslav R Efremov, Sergey I Bayborodin, Tamara V Tyrinova, Vyacheslav V Stupak, Alexandr A Ostatin, Elena R Chernykh and 1 more

Open access · goldAbstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in Technology in cancer research & treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

0.7field-weighted citation impact, top 29% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

Chronometric Administration of Cyclophosphamide and a Double-Stranded DNA-Mix at Interstrand Crosslinks Repair Timing, Called "Karanahan" Therapy, Is Highly Efficient in a Weakly Immunogenic Lewis Carcinoma Model.Pathology oncology research : POR · 2022
Article
The new general biological property of stem-like tumor cells Part I. Peculiarities of the process of the double-stranded DNA fragments internalization into stem-like tumor cells.Frontiers in genetics · 2022
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Evgeniya V Dolgova1 Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.

Sergey V Mishinov2 First Department of Neurosurgery, Ya. L. Tsivian Novosibirsk Research Institute of Traumatology and Orthopaedics, Novosibirsk, Russia.

Anastasiya S Proskurina1 Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.

Ekaterina A Potter1 Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.

Yaroslav R Efremov1 Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.

Sergey I Bayborodin1 Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.

Tamara V Tyrinova4 Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.

Vyacheslav V Stupak2 First Department of Neurosurgery, Ya. L. Tsivian Novosibirsk Research Institute of Traumatology and Orthopaedics, Novosibirsk, Russia.

Alexandr A Ostatin4 Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.

Elena R Chernykh4 Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.

Sergey S Bogachev1 Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.

Institute of Cytology and Genetics · RUResearch Institute of Fundamental and Clinical Immunology · RUNovosibirsk Scientific Research Institute of Traumatology and Orthopedics. Ya.L. Tsivyan · RUNovosibirsk State University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Poorly differentiated cell populations including tumor-initiating stem cells have been demonstrated to display a unique ability to natively internalize fragmented double-stranded DNA. Using this feature as a marker, we show that 0.1% to 6% of human glioblastoma cells from the bioptates can effectively internalize a fluorescently labeled DNA probe. Of these, using samples from 3 patients, 66% to 100% cells are also positive for CD133, a well-established surface marker of tumor-initiating glioma stem cells. Using the samples from primary malignant brain lesions (33 patients), we demonstrate that tumor grading significantly correlates ( R = .71) with the percentage of DNA-internalizing cells. No such correlation is observed for relapse samples (18 patients).

Indexed as

Biomarkers, TumorAC133 AntigenBrain NeoplasmsDNA, NeoplasmFluorescent Antibody TechniqueGliomaHumansNeoplasm GradingNeoplastic Stem CellsTumor Cells, CulturedAC133 AntigenBiomarkers, TumorDNA, NeoplasmCD133glioblastomaneurosphereTAMRA-DNAtumor-initiating stem cells

Identifiers

PMID29375020

DOI10.1177/1533034617753812

PMCPMC5789816

OpenAlexW2791320121

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.